Preschoolers to Get ADHD Drug Vyvanse in Shire Study
This article is for subscribers only.
Shire Plc will study its best-selling treatment for attention deficit hyperactivity disorder in preschool-age children as it seeks to expand the drug’s use.
Shire plans to begin the first of three studies on Vyvanse in 4- to 5-year-olds in the first half of 2015, the Dublin-based company said in a statement today. Given the Food and Drug Administration’s interest in reviewing safety and usage in young children, Shire submitted a proposed pediatric study request, which the FDA has now agreed to, Gwen Fisher, a Shire spokeswoman in Wayne, Pennsylvania, said by phone.